v3.8.0.1

Segment Information, Geographic Data, and Significant Customers | 12 Months Ended
--- | ---
Dec. 31, 2017
Segment Reporting [Abstract] |
Segment Information, Geographic Data, and Significant Customers | Segment Information, Geographic Data, and Significant Customers We have two reportable segments: Illumina’s core operations (Core Illumina) and one segment related to the combined activities of the consolidated VIEs, GRAIL and Helix (Consolidated VIEs). Following the GRAIL deconsolidation on February 28, 2017, the Consolidated VIEs no longer include GRAIL. Prior to 2016, the combined results of operations of the Consolidated VIEs were not material. We report segment information based on the management approach. This approach designates the internal reporting used by the Chief Operating Decision Maker (“CODM”) for making decisions and assessing performance as the source of our reportable segments. The CODM allocates resources and assesses the performance of each operating segment using information about its revenue and income (loss) from operations. Based on the information used by the CODM, we have determined its reportable segments as follows: Core Illumina: Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Core Illumina includes all of our operations, excluding the results of its consolidated VIEs. Consolidated VIEs: Helix: Helix was established to enable individuals to explore their genetic information by providing affordable sequencing and database services for consumers through third-party partners, driving the creation of an ecosystem of consumer applications. GRAIL: GRAIL was created to develop a blood test for early-stage cancer detection. GRAIL was in the early stages of developing this test and as such, had no revenues through the date of deconsolidation. Management evaluates the performance of our operating segments based upon income (loss) from operations. We do not allocate expenses between segments. Core Illumina sells products and provides services to GRAIL and Helix in accordance with contractual agreements between the entities. The following table presents the operating performance of each reportable segment (in millions):
| Years Ended
| December 31, 2017 |  | January 1, 2017 |  | January 3, 2016
Revenue: |  |  |  |  |
Core Illumina | $ | 2,754 |  |  | $ | 2,428 |  |  | $ | 2,220 |
Consolidated VIEs | 6 |  |  | — |  |  | — |
Eliminations | (8 | ) |  | (30 | ) |  | — |
Consolidated revenue | $ | 2,752 |  |  | $ | 2,398 |  |  | $ | 2,220 |
Depreciation and amortization: |  |  |  |  |
Core Illumina | $ | 153 |  |  | $ | 138 |  |  | $ | 127 |
Consolidated VIEs | 6 |  |  | 4 |  |  | — |
Eliminations | (3 | ) |  | (1 | ) |  | — |
Consolidated depreciation and amortization | $ | 156 |  |  | $ | 141 |  |  | $ | 127 |
Income (loss) from operations: |  |  |  |  |
Core Illumina | $ | 696 |  |  | $ | 684 |  |  | $ | 621 |
Consolidated VIEs | (92 | ) |  | (81 | ) |  | (8 | )
Eliminations | 2 |  |  | (16 | ) |  | — |
Consolidated income from operations | $ | 606 |  |  | $ | 587 |  |  | $ | 613 |
Other income (expense), net primarily relate to Core Illumina and we do not allocate income taxes to our segments. The following table presents the total assets and capital expenditures of each reportable segment (in millions):
| Years Ended
| December 31, 2017 |  | January 1, 2017 |  | January 3, 2016
Total assets: |  |  |  |  |
Core Illumina | $ | 5,223 |  |  | $ | 4,167 |  |  | $ | 3,658 |
Consolidated VIEs | 45 |  |  | 180 |  |  | 31 |
Eliminations | (11 | ) |  | (66 | ) |  | (1 | )
Consolidated total assets | $ | 5,257 |  |  | $ | 4,281 |  |  | $ | 3,688 |
Capital expenditures: |  |  |  |  |
Core Illumina | $ | 306 |  |  | $ | 238 |  |  | $ | 142 |
Consolidated VIEs | 4 |  |  | 22 |  |  | 1 |
Consolidated capital expenditures | $ | 310 |  |  | $ | 260 |  |  | $ | 143 |
The following table represents revenue by geographic area for the years ended December 31, 2017, January 1, 2017, and January 3, 2016 (in millions):
| Years Ended
| December 31, 2017 |  | January 1, 2017 |  | January 3, 2016
United States | $ | 1,511 |  |  | $ | 1,294 |  |  | $ | 1,207 |
Europe | 632 |  |  | 553 |  |  | 527 |
Greater China (a) | 292 |  |  | — |  |  | — |
Asia-Pacific (a) | 222 |  |  | 456 |  |  | 380 |
Other markets | 95 |  |  | 95 |  |  | 106 |
Total | $ | 2,752 |  |  | $ | 2,398 |  |  | $ | 2,220 |
(a) Revenue for the Greater China region, which includes China, Taiwan, and Hong Kong, became material for the year ended December 31, 2017. Therefore, such revenue is reported separately and the Asia-Pacific region no longer includes the Greater China region. Greater China region revenue is included in the Asia-Pacific region for the years ended January 1, 2017, and January 3, 2016. Revenue is attributable to geographic area based on the region of destination. The majority of our revenue consists of sales of consumables and instruments. For the years ended December 31, 2017, January 1, 2017, and January 3, 2016, consumable sales represented 64%, 64%, and 58%, respectively, of total revenue and instrument sales comprised 19%, 20%, and 27%, respectively, of total revenue. Our customers include leading genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. We had no customers that provided more than 10% of total revenue in the years ended December 31, 2017, January 1, 2017, and January 3, 2016. Net long-lived assets exclude goodwill and other intangible assets since they are not allocated on a geographic basis. We had net long-lived assets, consisting of property and equipment, in the following regions as of December 31, 2017 and January 1, 2017 (in millions):
| December 31, 2017 |  | January 1, 2017
United States | $ | 828 |  |  | $ | 636 |
Singapore | 54 |  |  | 44 |
United Kingdom | 43 |  |  | 28 |
Other countries | 6 |  |  | 5 |
Total | $ | 931 |  |  | $ | 713 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration